Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
Nightly administration of 8 mg of a unique sublingual (under the tongue) formulation of
tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve
next-day spasticity, about 12 hours following dosing in 20 multiple sclerosis (MS) patients.
This improvement was statistically significant when compared to oral tizanidine dosing. The
current study is being undertaken to see if increasing the dose to 12 mg once nightly will
result in an even greater improvement, with a longer effect, i.e., next day improvement in
spasticity both in the morning as well as in the late afternoon.